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INTRODUCTION
1
 
More than 90% of drugs are approved since 1995 have 
poor solubility. It is estimated that 40% of active new 
chemical entities (NCEs) identified in combinatorial 
screening programs employed by many pharmaceutical 
companies are poorly water soluble
1
. Drug absorption, 
sufficient and reproducible bioavailability and/or 
pharmacokinetic profile in humans are recognized today as 
one of the major challenges in oral delivery of new drug 
substances. Orally admin istered drugs on the Model list of 
Essential Medicines of the World Health Organizat ion 
(WHO) are assigned BCS classifications on the basis of 
data available in the public domain. Of the 130 orally  
administered drugs on the WHO list, 61 could  be classified  
with certainty. 84% of these belong to class I (highly 
soluble, highly permeable), 17% to class II (poorly soluble, 
highly permeable), 24 (39%) to class III (highly soluble, 
poorly permeable) and 6 (10%) to class IV (poorly soluble, 
poorly permeable). The rate and extent of absorption of 
class II & class IV compounds is highly dependent on the 
bioavailability which ultimately depends on solubility
2
. 
Due to this major reason, solubility and dissolution rate 
enhancement is one of the important parameters which  
should be considered in formulation development of orally  
administered drug with poor aqueous solubility
3
. 
A poorly water soluble drug, more recently, has been 
defined in general terms as a drug which requires more 
time to dissolve in the gastrointestinal fluid than it may  
take to get absorbed in the gastrointestinal tract and thus 
the ability to deliver poorly soluble drugs will grow in  
significance in the coming years as NCEs are relied upon 
for a larger share of the revenue within the pharmaceutical 
market by innovator companies. Similarly, generic drug 
manufacturers will need to employ economically efficient 
methods of delivery  as more low solubility drugs go off 
patent, in order to maintain a competit ive edge and 
sufficiently compete as profit margins shrink in this price-
sensitive industry
4
. 
Orally administered drugs should undergo dissolution in 
the gastro-intestinal fluids before absorption can 
commence. Insoluble or poorly soluble drugs are generally 
poorly absorbed from the gastro-intestinal tract after oral 
administration. The absorption behavior of such drugs can 
be best studied by in-vitro dissolution characteristics
6
.
  
Dissolution rate of drug plays a vital role in absorption of 
the drug from the dosage form and hence its 
bioavailability. When a drug is admin istered orally in solid 
dosage form (such as tablets or capsules), it is designed to 
undergo series of predetermined stages. The first step 
towards the absorption process is the disintegration of the 
dosage form. The second and in fact the slowest or rate-
limit ing step is found to be dissolution of drug in the fluid 
at the absorption site (Figure - 2). When dissolution is the 
controlling step in the overall process, absorption is said to 
be dissolution rate limited. Since the rate-limit ing step in 
the absorption process is dissolution of drug, therefore, any 
factor influencing the rate of dissolution must also 
influence the rate of absorption
7
. 
 
ABSTRACT 
In recent years, the formulation of poorly soluble compounds presented interesting challenges for formulation scientists in t he 
pharmaceutical industry. Up to 40% of new chemical entities discovered by the pharmaceutical industry are poorly soluble or 
lipophilic compounds, which lead to poor oral bioavailability, high intra and inter subject variability and lack of dose 
proportionality. This frequently results in potentially important products not reaching the market or not achieving their ful l 
potential. Poorly water-soluble drugs often require high doses in order to reach therapeutic plasma concentrations after oral 
administration. Improvement in the extent and rate of dissolution is highly desirable for such compounds, as this can lead to  an 
increased and more reproducible oral bioavailability and subsequently to clinically relevant dose reduction and more reliable 
therapy. The enhancement of dissolution rate and oral bioavailability is one of the greatest challenges in the development of 
poorly water soluble drugs. Experience with solid dispersions over the last 20-30 years indicates that this is a very fruitful 
approach to improving the solubility, dissolution rates and consequently the bioavailability of poorly soluble drugs. Solid 
dispersion is used to produce a homogeneous distribution of a small amount of drug in solid state.  This article summarize some 
of the practical aspects for the preparation of solid dispersion like selection of carrier ,method of physicochemical 
characterization, their advantages, limitations and applications along with an insight into the molecular arrangement of drug in 
solid dispersion. Solid dispersion technique is a very useful method for pharmaceutical point of view because of its capability to 
solve the solubility problems by using solid dispersion method.  
Key words: Solid dispersion, solubility, dissolution, selection of carriers  
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Figure 1: Good Medicines
5
 
According to dissolution theory, two important parameters 
determining the dissolution rate of a solid in a given 
solvent are: 
1) The solubility of the drug in the dissolution medium and  
2) The surface area of the drug exposed to the dissolution 
medium.
 
 
FIGURE 2: Sequence of the fate of drug after oral administration
8
 
Availability of a drug candidate in solution form at the 
absorption site is very important factor for the successful 
development and commercialization of new drugs & the 
dosage form in the pharmaceutical industry. No matter 
how active or potentially active a new molecular entity 
(NME) is against a particular molecu lar target, if it does 
not possess the above said property, it can not be a viable 
candidate for further development
9
.
  
Therefore, there is an almost requirement for improving 
the solubility of the drug candidate. A wide range of 
different technologies have been evolved in the recent past. 
A number of techniques of diverse nature are being 
presently utilized for enhancing the solubility of d rugs. 
SOLID DISPERS IONS  
In 1961, Sekiguchi and Obi first proposed the utilization of 
solid dispersions to increase the dissolution and oral 
absorption of poorly water-soluble drugs. They proposed 
the formation of a eutectic mixture of a poorly water-
soluble drug with a physiologically inert, easily soluble 
carrier (Chiou and Riegelman, 1969). In 1971 Chiou and 
Riegelman defined solid dispersion as  “the dispersion of 
one or more active ingredients in an inert carrier matrix at  
solid-state prepared by the melting (fusion), solvent or 
melting-solvent method”. The solid dispersions may also 
be called solid-state dispersions, as first used by 
Mayersohn and Gibaldi (1966). Corrigan defined the term 
as “product formed by converting a fluid drug-carrier 
combination to the solid state” (Corrigan 1985). In a recent 
review work by Dhirendra et al. adopted the definition 
given by Chiou and Riegelman “a group of solid products 
consisting of at least two different components, generally a 
hydrophilic matrix and a hydrophobic drug”. The matrix 
can be either crystalline or amorphous. The drug can be 
dispersed molecularly, in amorphous  particles (clusters) or 
in crystalline part icles” (Dhirendra et al., 2009). But if the 
drug is converted to amorphous form and forms  one phase 
system with polymer, it can be classified as a solid 
solution, whereas if the drug exists as microcrystalline 
dispersion, i.e., forms two-phase system, it is generally  
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referred to as a solid dispersion (Goldberg et al., 1965;  
Sekiguchi and Obi 1961; Chokshi et al., 2007)
 10
.  
Solid dispersion is a well-known approach for 
improvement of the dissolution rate and bioavailability of 
drugs that are poorly water soluble. To achieve faster 
dissolution rate of poorly water-soluble drug, the drug is 
dispersed at molecu lar level in a rapidly water-soluble 
inert carrier to form a solid dispersion. Successful 
dispersion of the drug in the carrier, at molecular level, 
leads to formation of homogeneous phase of the solid 
dispersion. When such a product comes in contact with 
gastric fluid, then the water-soluble carrier rapidly  
dissolves leading to immediate release of the drug at the 
desired molecular level to cause dissolution with 
consequent improvement of bioavailability. Solid  
dispersions have been extensively studied for improvement 
of dissolution rate and numerous  techniques of diverse 
nature have been developed for preparation of the same
11
.  
Because of the simplicity of manufacturing and scale up 
processes, the popularity of the solid dispersion systems  to 
solve difficu lt bioavailability issues with respect to poorly 
water-soluble drugs will grow rapidly. Because the dosage 
form can be developed and prepared by using small 
amounts of drugs substances in early stages of the drug 
development process, the system might have an advantage 
over such other commonly used bioavailability 
enhancement techniques as micronizat ion of drugs and soft 
gelatin encapsulation. Single or combination of carriers 
may also be essential for development of solid  
dispersion
12
.  
The drug in the solid dispersion may present as crystalline 
particles, amorphous particles or molecularly dispersed; as 
shown in the figure 3: 
 
Figure 3: Forms of the drug in solid dispersion
13
 
IDEAL DRUG CANDIDATES FOR SOLID 
DISPERS ION 
In the Biopharmaceutical Classification Sys tem (BCS) 
class II drugs are those with low aqueous solubility and 
high membrane permeability and therefore solid dispersion 
technologies are particularly promising for improving the 
oral absorption and bioavailability of BCS Class II drugs . 
According to the BCS, d rug substances can be classified as 
belonging to one of four classes, Ahmad Zaheer et al 
(2011)
 14
.  
Class I: High permeability and solubility.  
Formulation independent: - The bioavailability of class I 
compounds is determined only by delivery of the drug 
solution to the intestine. 
Examples: Benzapril, Loxoprofen, Sumatriptan etc. 
Class II: high permeability but low solubility 
Formulation dependent: - The bioavailability of class II 
compounds is limited by drug solubility/dissolution. 
Examples: Valsartan, Nimesulide, Loratadine, Aceclofenac 
etc. 
Class III: low permeability but high solubility 
Dependent on barrier properties: - The b ioavailab ility of 
class III compounds is limited by intestinal permeability.  
Examples: Gabapentine, Topiramate, Atropine etc. 
Class IV: low permeability and low solubility 
Formulation and barrier properties dependent: - The 
bioavailability of class IV compounds is limited both by 
solubility / dissolution and intestinal permeability. 
Examples: Hydrochlorthiazide, Furosemide,  Meloxicam 
etc. 
Among the four classes class II drugs shows poor 
solubility and high permeability. It is obvious that for class 
II drugs the low ability to dissolve is a more important 
limitat ion to their overall rate and extent of absorption then 
their ability to permeate through the membrane. Therefore, 
the formulation work for class II compounds should focus 
on the enhancement of aqueous solubility or dissolution 
rate 
15
.  
CLASSIFICATION OF SOLID DISPERSION 
(1) Simple Eutectic Mixtures: A simple eutectic mixture 
consists of two compounds which are completely miscible 
in the liquid state but only to a very limited extent in the 
solid state
16
.  
 
Figure 4: Phase diagram for a Eutectic mixture
16
 
(2) Amorphous Precipitations  in a Crystalline Carrier:  
This type of solid dispersion is distinguished from a simple 
eutectic mixture by the fact that the drug is precip itated out 
in an amorphous form. In a simple eutectic mixture, the 
drug is precipitated out in a crystalline form. It is 
postulated that a drug with a propensity to super cooling 
has more tendency to solidify as an amorphous form in the 
presence of a carrier
17
.  
(3) Solid solutions: So lid solutions of a poorly water 
soluble drug dissolved in a carrier with relatively good 
aqueous solubility are of particular interest as a means of 
improving oral b ioavailability. In the case of solid  
solutions, the drug's particle size has been reduced to its 
absolute minimum v iz. the molecular dimensions and the 
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dissolution rate are determined by the dissolution rate of 
the carrier
17
.  
3.1) Continuous solid solutions- In a continuous solid 
solution, the components are miscible in all proportions. 
Theoretically, th is means that the bonding strength 
between the two components is stronger than the bonding 
strength between the molecules of each of the individual 
components. Solid solutions of this type have not been 
reported in the pharmaceutical literature to date
16
.  
3.2) Discontinuous solid solutions- In the case of 
discontinuous solid solutions, the solubility of each of the 
components in the other component is limited. The phase 
diagram in Fig. 5 shows the regions of true solid solutions. 
In these regions, one of the solid components is completely  
dissolved in the other solid component
17
.  
 
Figure 5: Phase diagram for a discontinuous solid 
solution
17
 
3.3) Substitutional crystalline solid solutions- Classical 
solid solutions have a crystalline structure, in which the 
solute molecules can either substitute for solvent 
molecules in the crystal lattice or fit into the interstices 
between the solvent molecules. Substitution is only 
possible when the size of the solute molecu les differs by 
less than 15% or so from that of the solvent molecu les
17
.  
 
Figure 6: Substitutional crystalline solid solution
17
 
3.4) Interstitial crystalline solid solutions: In interstitial 
solid solutions, the dissolved molecules occupy the 
interstitial spaces between the solvent molecules in the 
crystal lattice. In the case of interstitial crystalline solid  
solutions, the solute molecules should have a molecu lar 
diameter that is no greater than 0.59 of the solvent 
molecule's molecular d iameter.  
3.5) Amorphous solid solutions: In an amorphous solid 
solution, the solute molecules are dispersed molecularly  
but irregularly within the amorphous solvent. Polymer  
carriers (viz. PVP, PEG, cellulose derivatives etc) are 
particularly likely to form amorphous` solid solutions as 
the polymer itself is often present in the form of an 
amorphous polymer chain network. In addition, the solute 
molecules may serve to plasticize the polymer, leading to a 
reduction in its glass transition temperature
16
.  
 
Figure 7: Interstitial crystalline solid solution
16
 
 
Figure 8: Amorphous solid solution
16
 
(4) Glass solution and Glass suspension: A „Glass 
solution‟ is a homogenous, glassy system in which a solute 
dissolves in the glassy solvent, where as „Glass 
suspension‟ refers to a mixture in which precipitated 
particles are suspended in a glassy solvent. The glassy 
state is characterized by transparency and brittleness below 
the glass transition temperature. Glasses do not have sharp 
melting points. Instead, they soften progressively on 
heating. The lattice energy, which represents a barrier to 
rapid dissolution, is much lower in g lass solutions than in 
solid solutions
18
. 
 
(5) Compound or Complex Formation: Complex 
formation (soluble and insoluble) can enhance or reduce 
the dissolution of drugs e.g. Quinidine-Phenobarbitone 
system increases dissolution whereas PEG-Phenobarbitone 
system reduces the dissolution. Various types of 
cyclodextrins are usually used to enhance the solubility  of 
drugs via complexat ion
19
. 
 
SELECTION OF CARRIERS US ED IN SOLID 
DISPERS ION 
The selection of the carrier has the influence on the 
dissolution characteristics of the dispersed drug s ince the 
dissolution rate of one component from the surface is 
affected by the other component in a multi component 
mixture. Therefore a water soluble carrier results in a 
faster release of the drug from the matrix. A poorly soluble 
Reena et al                                      Journal of Drug Delivery & Therapeutics; 2012, 2(4), 5-14    9 
© 2011, JDDT. All Rights Reserved                                                          ISSN: 2250-1177                                                   CODEN (USA): JDDTAO 
or insoluble carrier leads to slower release of a drug from 
the matrix. The carriers to be used should have the 
following characteristics:
 20 
1. Readily soluble in water and in gastrointestinal fluids  
2. Physiologically inert  
3. Melting point not much higher than that of drug 
4. Thermal stability at melting temperature  
5. Low vapour pressure 
6. High molecular weight 
7. They should be non toxic  
CARRIERS IN SOLID DISPERS ION  
Polyethylene glycol: Polyethylene glycols (PEGs) are 
polymers of ethylene oxide, with a molecular weight 
(MW) usually falling in the range 200 ± 3,00,000. Their 
solubility in water is generally good, but decreases with 
MW. A particular advantage of PEGs for the formation of 
solid dispersions is that they also have good solubility in  
many organic solvents. The melt ing point of the PEGs of 
interest lies under 65°C in every  case (e.g. the m.p. of PEG 
1000 is 30-40°C, the m.p. of PEG 4000 is 50-58°C and the 
m.p. of PEG 20,000 is 60-63°C)
 21
. These relatively low 
melting points are advantageous for the manufacture of 
solid dispersions by the melt ing method. PEGs of MW 
4000-6000 are the most frequently used for the 
manufacture of solid dispersions, because in this MW 
range the water solubility is still very high, but hygroscopy 
is not a problem and the melt ing points are already over 
50°C. If a PEG with too low a MW is used, this can lead to 
a product with a sticky consistency that is difficu lt to 
formulate into a pharmaceutically acceptable product
22
.  
Poly vinyl pyrrolidone: Polymerizat ion of 
vinylpyrrolidone leads to polyvinylpyrrolidone (PVP) of 
molecular weights ranging from 2500 to 3,000,000. These 
can be classified according to the K value. Due to their 
good solubility in a wide variety of organic solvents, they 
are particularly suitable for the preparation of solid 
dispersions by the solvent method. PVPs have good water 
solubility and can improve the wettability of the dispersed 
compound in many cases. The chain length of the PVP has 
a very significant influence on the dissolution rate of the 
dispersed drug from the solid dispersion. The aqueous 
solubility of the PVPs becomes poorer and viscosity 
lowers with increasing chain length
23
.  
Urea: Urea is the end product of human protein 
metabolism, has a light diuretic effect and is regarded as 
non-toxic. Its solubility in water is greater than 1 in 1 and 
it also exhib its good solubility in many common organic 
solvents. In one of the first bioavailability studies of solid 
dispersions, it was shown that sulphathiazole was better 
absorbed in rabbits when given as a eutectic with urea
24
.   
Sugars: Although sugars and related compounds are 
highly water soluble but few sugars have toxicity issues, 
they are less suitable than other carriers for the 
manufacture of solid dispersions. Lactose is useful as a 
carrier for the production of solid dispersions of drugs 
prepared by melting and rapid cooling showed marked  
increase in dissolution rate. Chitosan has also been used as 
a carrier in solid dispersions. Mannitol can be employed in 
some cases to prepare dispersions by the hot melt  
method
25
.
   
Emulsifiers: The release behaviour of many drugs can 
also be improved through the use of emulsify ing agents. 
Two mechanis ms are possible here: improvement of 
wetting characteristics and solubilizat ion of the drug. 
Owing to their potential toxicity problems, such as damage 
to mucosal surfaces, they are used in combination with 
another carrier. Surfactants are suitable carriers for low 
dose and very low water soluble drugs
26
. Poloxamers are 
nonionic triblock copolymers . Because of their 
amphiphilic structure, the polymers have surfactant 
properties that make them useful in industrial applications. 
The recently used surface-active carrier is Gelucire® 44/14 
and other grades of Gelucire®. Bile salts and their 
derivatives are natural surfactants; they enhance the 
wetting and solubility of many lipophilic substances, 
leading to an increase in dissolution rate.  
Polyacrylates and polymethacrylates: Polyacrylates and 
polymethacrylates are glassy substances that are produced 
by polymerizat ion of acrylic and methacrylic acid, and 
derivatives of these polymers such as esters amides and 
nitriles. In pharmaceuticals they are mostly used in 
coatings to modify the release of the drug from the dosage 
form. Commonly they are referred by the trade name 
Eudragit
25
.  
Cellulose derivative: Celluloses are naturally occurring 
polysaccharides that are ubiquitous in the plant kingdom. 
They consist of high molecular weight unbranched chains, 
in which the saccharide units are linked by β-1, 4-
glycoside bonds. By appropriate alkylation, the cellulose 
can be derivatized to form methyl- (MC), hydroxypropyl 
(HPC), hydroxypropylmethyl (HPMC) and many other 
semi-synthetic types of cellulose. A further possibility for 
derivatization is the esterification of the cellulose to form 
compounds such as cellulose acetate phthalate (CAP) and 
hydroxypropylmethylcellulose phthalate (HPMCP)
 25
.  
ADVANTAGES  OF SOLID DISPERS IONS 
1. Particles with reduced particle size and increased 
dissolution rate: Solid dispersions represent the last state 
on particle size reduction and after carrier d issolution the 
drug is molecularly dispersed in the dissolution medium. 
Solid dispersions apply this principle to drug release by 
creating a mixture of a poorly water soluble drug and 
highly soluble carriers. Due to this a high surface area is 
formed resulting in an increased dissolution rate and 
improved bioavailab ility
27
. 
 
2. Particles with improved wettability: A strong 
contribution to the enhancement of drug solubility is 
related to the drug wettability improvement verified in  
solid dispersions. It was observed that even carriers 
without any surface activity, such as urea improved drug 
wettability. Carriers with surface activity such as cholic 
acid and bile salts when used can significantly increase the 
wettability property of drug. Moreover, carriers can 
influence the drug dissolution profile by direct dissolution 
or co-solvent effects. 
3. Particles with higher porosity: Particles in solid 
dispersions have been found to have a higher degree of 
porosity. The increase in porosity depends on the carrier 
properties, for instance solid dispersions containing linear 
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polymers produce larger and more porous particles than 
those containing reticular polymers and so result in a 
higher dissolution rate. The increased porosity of solid 
dispersion particles also hastens the drug release profile
27.
 
4. Drugs in amorphous state: Poorly water soluble 
crystalline drugs, when in the amorphous state tend to have 
higher solubility. The enhancement of drug release can 
usually be achieved using the drug in its amorphous state, 
because no energy is required to break up the crystal lattice 
during the dissolution process
27
. 
 
 
Figure 9: Advantages of a solid dis persion formulation, as compared to conventional capsule or tablet
28.
 
DISADVANTAGES OF SOLID DISPERS IONS  
1. Laborious and expensive methods of preparation, 
2. Stability of the drug and vehicle.  
3. Due to tackiness in some solid dispersion, it sometimes 
leads to    handling problem. 
4. Reproducibility of physicochemical characteristics. 
5. Difficulty in incorporating into formulat ion of dosage 
forms. 
6. Scale-up of manufacturing process. 
METHODS OF PREPARATION 
Fusion method: Accurately weighed drug and carrier are 
mixed using glass mortar and pestle. The mixture is heated 
at or above the melting point of all the components to 
achieve a homogenous dispersion. It is then cooled to 
obtain a congealed mass. It is pulverized and sieved. Ex. 
albendazole and urea solid dispersion was prepared this 
method
29
.  
Advantages: The main advantage of direct melt ing 
method is its simplicity and economy. In addition melt ing 
under vacuum or blanket of an inert gas such as nitrogen 
may be employed to prevent oxidation of drug or  carrier. 
Disadvantages: Firstly, a major disadvantage is that the 
method can only be applied when drug and matrix are 
compatible and when they mix well at the heating 
temperature. Secondly, a problem can arise during cooling 
when the drug-matrix miscibility changes. In this case 
phase separation can occur. Thirdly, degradation of the 
drug and or matrix can occur during heating to 
temperatures necessary to fuse matrix and drug. 
Solvent method: Drug and carrier both are dissolved in 
organic solvent. After complete dissolution, the solvent is 
evaporated. The solid mass is ground, sieved and dried. 
Ex. Solid dispersion of oflo xacin with polyethylene glycol 
was prepared by solvent evaporation method
29
.  
Advantages: The main advantage of the solvent method is 
that thermal decomposition of drugs or carriers can be 
prevented because of the low temperature required for 
evaporation of organic solvents. 
Disadvantages: The disadvantages include the higher cost 
of preparation, the difficulty in completely removing liquid  
solvent.   
Supercritical fluid methods: Supercritical fluid methods 
are mostly applied with carbon dioxide, which is used as 
either a solvent for drug and matrix or as an anti-solvent. 
When supercritical CO2 is used as solvent, matrix and 
drug are dissolved and sprayed through a nozzle, into an 
expansion vessel with lower pressure and particles are 
immediately formed. The adiabatic expansion of the 
mixture results in rapid cooling. This technique does not 
require the use of organic solvents and since CO2 is  
considered environmentally friendly, th is  technique is 
referred to as „solvent free‟. The technique is known as 
Rapid Expansion of Supercrit ical So lution
29
.  
Advantages: The supercritical anti-solvent rapidly 
penetrates into the droplets, in which drug and matrix 
become supersaturated, crystallize and form part icles. The 
general term for this process is  precipitation with 
compressed anti- oven. 
Disadvantages: Usually organic solvents like  
dichloromethane or methanol have to be applied to 
dissolve both drug and matrix which are more in cost. 
Melting solvent method: In this method drug is first 
dissolved in a suitable liquid solvent Solution is then 
incorporated directly into the melt of polyethylene glycol 
obtainable below 70C, without removing the liquid 
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solvent. It has been shown that 5-10% (w/w) of liquid  
compound could be incorporated into polyethylene glycol 
6000 without significant loss of its solid property
30
.  
Advantages: In this method that thermal decomposition of 
drugs or carriers can be prevented because of the low 
temperature required for evaporation of organic solvents. 
Disadvantages: As the practical point of view, the 
melting-solvent method is limited to drugs with a low 
therapeutic dose, e.g., below 50mg.  
Melt agglomeration process: This technique has been 
used to prepare solid dispersion where the binder acts as a 
carrier. Binder (carrier), drug and excipients are heated to 
temperature above the melting point of the binder (melt -in  
procedure) or by spraying a dispersion of drug in molten 
binder on the heated excipient (spray-on procedure) by 
using a high shear mixer. The rotary processor might be 
preferable to the high melt agglomeration because it is 
easier to control the temperature and higher binder content 
can be incorporated in the agglomerates. Larger particles 
result in densification of agglomerates while fine particle 
cause complete adhesion to the mass to bowl shortly after 
melting attributed to distribution and coalescence of the 
fine part icles
30
.  
Spray drying: It is a method which is initiated by 
atomizing suspensions or solutions into fine droplets 
followed by a drying process, resulting in solid particles. 
The process allows production of fine, dust free powder as 
well as agglomerated one to precise specifications. The 
operating conditions and dryer design depends upon the 
drying characteristics of the product and require powder 
specifications. The spray drying technique is a useful 
method to obtain spherical particle and narrow 
distribution
31
.  
The use of surfactant: Surfactant reduces hydrophobicity 
of drug by reducing interfacial or surface tension and 
because of this unique property surfactants  have attracted 
the attention of investigators for preparation of solid 
dispersions. Recently a new class of surfactant known as 
Gelucires are introduced which identify by melting points 
and HLB values. Gelucire is widely used in the 
formulat ion of solid d ispersions. Poloxamer represent 
another class of surfactants. Polysorbate 80 a surfactant 
results in improvement of dissolution and bioavailability of 
poorly water soluble drug attributed to the solubilisation 
effect of surface active agent
32
.  
Alternative strategies 
Spraying on sugar beads using a fluidized bed coating  
system: 
The approach involves a fluidized bed coating system, 
wherein a drug-carrier solution is sprayed onto the 
granular surface of excipients or sugar spheres to produce 
granules ready for tabletting or drug coated pellets for 
encapsulation in one step. The method has been applied for 
both controlled and immediate release solid dispersions
33
.  
Itraconazole (Sporanox oral capsules, Janssen 
Pharmaceutica, Titusville, NJ) coated on sugar sphere, is 
made by layering onto sugar beads a solution of drug and 
hydroxypropylmethylcellulose (HPMC) in an organic 
solvent of dichloromethane and ethanol. A solid solution 
of drug in HPMC is produced upon coating (cosolvent 
evaporation) and controlled drying of coated beads in a 
closed Wurster process. As this thin film d issolves in water 
or gastric flu id, the molecularly dispersed itraconazole is 
released at supersaturated concentration. HPMC acts as a 
stabilizer to inhibit recrystallization of the itraconazole. 
The supersaturated solutions of itraconazole are 
sufficiently stable to allow for absorption and distribution. 
Hot melt extrusion: It has been reported that melt  
extrusion of miscible components results in amorphous 
solid solution formation, whereas extrusion of an 
immiscible component results to amorphous drug 
dispersed in crystalline excipient
34
. The process has been 
useful in the preparation of solid dispersions in a single 
step. Hot-melt extrusion method is used in the preparation 
of various dosage forms in the pharmaceutical industry 
such as preparation of sustained-release pellets. The 
advantages of hot-melt ext rusion include lower 
temperature and shorter residence time of the drug carrier 
mix (<2 minutes), absence of organic solvents, continuous 
operation possibility, min imum product wastage, good 
control of operating parameters, and possibility to scale up. 
The disadvantages are few and main ly relate to negative 
effects of shear force.  
Direct capsule filling: The filling of semisolid materials 
into hard gelatin capsules as melts, which solidify at room 
temperature, was first done in 1978. Laboratory-scale 
semiautomatic equipment and large-scale manufacturing 
equipment for direct capsule filling are commercially  
available. Direct filling of hard gelatin capsules with the 
liquid  melt of solid d ispersions avoids grinding-induced 
changes in the crystallinity of the drug. The filling of hard 
gelatin capsules has been feasible in molten dispersions of 
triamterene-PEG 1500 using a Zanasi LZ 64 capsule-
filling machine (Zanasi Co, Bologna, Italy). This molten 
dispersion forms a solid plug inside the capsule on cooling 
to room temperature, reducing crosscontamination and 
operator exposure in a dust-free environment better fill 
weight and content uniformity was obtained than with the 
powder-fill technique. However, PEG was not a suitable 
carrier fo r the direct capsule-filling method as the water-
soluble carrier dissolved more rapidly than the drug, 
resulting in drug-rich layers formed over the surface of 
dissolving plugs, which prevented further dissolution of 
the drug
35
. A surfactant must be mixed with the carrier to 
avoid format ion of a drug-rich surface layer (eg, 
polysorbate 80 with PEG). 
Electrostatic spinning method: The electrostatic spinning 
method technology used in the polymer industry combines 
solid solution/dispersion technology with nanotechnology. 
This technology is now applied in the pharmaceutical field. 
In this process, a liquid stream of a drug/polymer solution 
is subjected to a potential between 5 and 30 kV. When 
electrical forces overcome the surface tension of the 
drug/polymer solution at the air interface, fibers of 
submicron diameters are formed. Water-soluble polymers 
would be useful in the formulat ion of immediate release 
dosage forms, and water-insoluble (both biodegradable and 
nonbiodegradable) polymers are useful in controllable 
dissolution properties. Fabrics generated by water-soluble 
carriers could be used in oral dosage formulations by direct 
incorporation of the materials into a capsule.  
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Surface active carriers: A surface-active carrier may be 
preferable in almost all cases for the solid dispersion of 
poorly water-soluble drugs. In addition to their use as 
excip ients to improve the physical and chemical 
characteristics of the formulat ion, surface active carriers 
may be included to improve the efficacy of the product. 
The properties of surfactant are such that they can alter the 
thermodynamic activ ity, solubility, diffusion, 
disintegration and dissolution rate of a drug. Each of these 
parameters influences the rate and extent of drug 
absorption. Surface active carriers can exert direct effects 
on biological membranes thus altering drug transport 
across the membrane
36
. The surface-active and self-
emulsifying carriers for solid d ispersion of poorly water-
soluble drugs have been of great interest in recent years. 
Two of the important surface-active carriers are Gelucire 
44/14 and Vitamin E R-alpha-tocopheryl polyethylene 
glycol 1000 succinate (TPGS).  
 
Figure 10: Relative dissolution rate of solid dis persions containing surface active carrier, compared to non-surface 
active carrier
37
 
CHARACTERIZATION OF SOLID DISPERS ION 
A.Detection of crystallinity in solid dispersions: Several 
different molecu lar structures of the drug in the matrix can  
be encountered in solid dispersions. Many attempts have 
been made to investigate the molecular arrangement in  
solid dispersions. Many techniques are available which  
detect the amount of crystalline material in the dispersion. 
Currently, the following techniques are available to 
detect the crystallinity: 
1. Powder X-ray di ffraction: It can be used to 
qualitatively detect material with long range order. 
Sharper diffraction peaks indicate more crystalline 
material
38
.  
2. Infrared spectroscopy (IR): It can be used to detect 
the variation in  the energy distribution of interactions 
between drug and matrix. Sharp vibrational bands 
indicate crystallin ity. Fourier Transformed Infrared  
Spectroscopy was used to accurately detect 
crystallinit ies ranging from 1 to 99% in pure 
material
39
.  
3. Isothermal Microcalorimetry: It measures the 
crystallization energy of amorphous material that is 
heated above its glass transition temperature (Tg)
 39
.  
4. Dissolution Calorimetry: It measures the energy of 
dissolution, which is dependent on the crystallinity of 
the sample; usually dissolution of crystalline material 
is endothermic, whereas dissolution of amorphous 
material is exothermic
40
.  
5. Macroscopic techniques  can be indicative for the 
degree of crystallin ity. Density measurements and 
Dynamic Mechanical Analysis (DMA) determine the 
modulus of elasticity and viscosity and thus affected 
by the degree of crystallinity.  
6. A technique used to detect the amount of 
crystalline material is Differential Scanning  
Calorimetry (DSC). In DSC, samples are heated with 
a constant heating rate and the amount of energy 
necessary for that is detected. With DSC the 
temperatures at which thermal events occur can be 
detected. Also the melt ing and crystallization energy 
can be quantified. The melt ing energy can be used to 
detect the amount of crystalline material.  
B.Detection of molecular structure in amorphous solid 
dis persions 
The properties of a solid dispersion are highly affected by 
the uniformity of the distribution of the drug in the matrix. 
The following techniques are used: 
1. Confocal Raman S pectroscopy was used to measure 
the homogeneity of the solid mixture of ibuprofen in 
PVP. It was described that a standard deviation in 
drug content smaller than 10% was indicative of 
homogeneous distribution
41
.  
2. Using IR or FTIR, the extent of interactions between 
drug and matrix can be measured. The interactions are 
indicative for the mode of incorporation of the drug, 
because separately dispersed drug molecules will have 
more drug-matrix interactions than when the drug is 
present in amorphous clusters
42
.  
3. Temperature Modulated Differential Scanning  
Calorimetry (TMDSC) can be used to assess the 
degree of mixing of an incorporated drug. Due to the 
modulation reversible and irreversib le events can be 
separated. This technique can be used to assess the 
amount of molecularly d ispersed drug and from that 
the fraction of drug that is dispersed as separate 
molecules is calculated
43
.       
MARKETED PRODUCTS  
Commercial products based on solid solution /  dispersion 
are: 
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1. Gris-PEG, a griseofulvin-PEG fusion method solid 
dispersion, was manufactured init ially by Dorsey / 
Sandoz and reached the market in the mid- 
1970s.Gris-PEG was developed as tablet product, and 
this led to two USP monographs for griseofulvin 
tablets. The solid dispersion form is referred to as 
ultramicrosize griseofulvin tablets USP and offers 
improved bioavailability and two- thirds reduced 
dosage compared to griseofulvin tablets USP. The 
griseofulvin tablets USP are manufactured from 
micronized drug substance using a conventional 
tabletting approach. Griseofulvin solid dispersion 
tablets are currently marketed by a number of 
manufacturers and contain corn starch, lactose, 
magnesium stearate, PEG, and sodium laury l sulfate 
as inactive  ingredients
29
. 
2. Cesamet, a nabilone-PVP solvent method solid 
dispersion manufactured by Eli Lilly and Co. has been 
marketed internationally since 1982. Eli Lilly  
discontinued marketing Cesamet contains PVP and 
corn starch as inactive ingredients and is presented as 
a capsule product
44
. 
3. Solid dispersion formulat ion of Troglitazone (Rezulin) 
is marketed by Parke-Davis
45
.  
4. Solid solutions of lopinavir and ritonavir in 
polyvinylpyrrolidone-vinyl acetate copolymer 
successfully enabled a reformulation of "Kaletra" ( 
Abbott Laboratories, Abbott Park, IL). In addition to 
reducing the dosage burden from six softgel capsules 
to four tablets, tablets made with the solid solutions 
eliminate the need for refrigeration
29
. 
5. "Sporanox" (Janssen Pharmaceutica, Titusville, NJ) is 
a solid dispersion of itraconazole in hypromellose that 
has been layered onto sugar spheres
29
. 
6. The most recently approved product is the 
nonnucleoside reverse transcriptase inhibitor 
"Intelence" (Tibotec, Yardley, PA), an amorphous, 
spray-dried solid dispersion of etravirine, 
hypromellose, and microcrystalline cellu lose
46
. 
APPLICATION OF SOLID DISPERS ION IN 
PHARMA INDUS TRIES  
1. Increases oral bioavailability of poorly water-soluble 
drugs 
2. Solid state suitable for oral delivery  
3. No change in chemical properties of the drug 
4. Relatively simple processing techniques 
5. Uses conventional equipment 
6. Increases dissolution due to metastable solid state 
7. To obtain a homogeneous distribution of a small 
amount of drug in solid state 
8. To stabilize the unstable drug. 
9. To dispense liquid (up to 10%) or gaseous compounds 
in a solid dosage. 
10. To formulate a fast release primary dose in a sustained 
released dosage form. 
11. To formulate sustained release regimen of soluble 
drugs by using poorly soluble or insoluble carriers. 
12. To reduce pre systemic inactivation of drugs like 
morphine and progesterone. 
FUTURE POTENTIAL OF SOLID DISPERS ION 
The solubility of drugs in aqueous media is a key factor 
highly influencing their dissolution rate and bioavailability 
following oral admin istration resulting in low 
bioavailability. Solubility enhancement of these drugs 
remains one of the most challenging aspects of drug 
development. A variety of devices have been developed 
over the years to enhance the drug solubility and 
dissolution of the drugs. The solid dispersion method is 
one of the effective approaches to achieve the goal of 
solubility enhancement of poorly water-soluble drugs. 
Various techniques, described in this review, are 
successfully used for the preparation of SD(s) in the bench 
and lab scale and can be used at industrial scale also. Solid 
dispersions came into limelight in pharmaceutical 
development due to the increasing number of drug 
candidates which are poorly soluble and the substantial 
improvements in the manufacturing methods for solid 
dispersions that have been made in the last few years. 
Although there are some hurdles like scale up and 
manufacturing cost to overcome, there lies a great promise 
that solid dispersion technology will hasten the drug 
release profile of poorly water soluble drugs, Ahuja et al 
(2007). 
Despite many advantages of solid dispersion, issues related 
to preparation, reproducibility, formulation, scale up, and 
stability limited its use in commercial dosage forms for 
poorly water-soluble drugs. Successful developments of 
solid dispersion systems for preclinical, clinical and 
commercial use have been feasible in recent years due to 
the availability of surface-active and self-emulsify ing 
carriers with relatively low melt ing points. The preparation 
of dosage forms involves the dissolving of drugs in melted 
carriers and the filling of the hot solutions into gelatin 
capsules. Because of the simplicity of manufacturing and 
scale up processes, the physicochemical properties and as 
expected to change significantly during the scale up. For 
this reason, the popularity of the solid dispersion systems 
to solve difficult bioavailability issues with respect to 
poorly water-soluble drugs will grow rap idly. 
CONCLUS ION 
As poorly water-soluble compounds become more 
prevalent in the pharmaceutical markets, there are 
increased attempts for enhancing oral bioavailability of 
these drug candidates. Solid dispersions are one of the 
most promising strategies to solve this problem.  
Experience with solid dispersions over the last 20-30 years 
indicates that this is a very fru itful approach to improving 
the release rate and oral b ioavailability of poorly water 
soluble drugs and the availability of a wide variety of 
polymers that are themselves poorly soluble or which 
swell under aqueous conditions suggests that solid  
dispersions have tremendous potential in the area of 
controlled release dosage forms. Because of solubility 
problem of many drugs the bio availability of them gets 
affected and hence solubility enhancement becomes 
necessary. Solid dispersion technology is one of the 
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possible modes that increase the solubility of poorly 
soluble drugs. Successful development of solid dispersion 
system for preclinical, clinical and commercial use has 
been feasible in recent years  due to the availability of 
surface active carriers and self emulsifying carriers. 
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